Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy

Clinical Lymphoma and Myeloma

Volumn 7, Issue 3, 2006, Pages 236-238

  Shah, Jatin J ^a   Meredith, Ruby ^a   Shen, Sui ^a   Nabors, Burt ^a   Lobuglio, Albert ^a   Yester, Michael ^b   Forero, Andres ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Ibritumomab tiuxetan; Methotrexate; Monoclonal antibodies

Indexed keywords

ANTIBIOTIC AGENT; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; INDIUM 111; METHOTREXATE; RITUXIMAB;

ADULT; ARTICLE; ASTROCYTOMA; B CELL LYMPHOMA; BRAIN BIOPSY; BRAIN LYMPHOMA; BRAIN SCINTISCANNING; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CRANIOTOMY; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE QUALITY; INFECTION; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; RADIOIMMUNOTHERAPY; STEREOTAXIC SURGERY; THROMBOCYTOPENIA; TUMOR LOCALIZATION;

ADULT; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; PROGNOSIS; RADIOIMMUNOTHERAPY; REMISSION INDUCTION;

EID: 37849185874     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Nakhleh RE, Manivel JC, Hurd D, et al. Central nervous system lymphomas: immunohistochemical and clinicopathologic study of 26 autopsy cases. Arch Pathol Laby Med 1989; 113:1050-1056.
2. Rampen FH, van Andel JG, Sizoo W, et al. Radiation therapy in primary non Hodgkin's lymphomas of the CNS. Eur J Cancer 1980; 16:177-184.
3. Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 1999; 43:241-247.
4. Lachance DH, Brizel DM, Gockerman JP, et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma. Short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 1994; 44:1721-1727.
5. Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group protocol 88-06. J Clin Oncol 1996; 14:556-564.
6. Shibamoto Y, Tsutsui K, Dodo Y, et al. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer 1990; 65:1907-1912.
7. Glass J, Shustik C, Hochberg FH, et al. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neurooncol 1996; 30:257-265.
8. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10. J Clin Oncol 2002; 20:4643-4648.
9. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003; 21:1044-1049.
10. Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81:188-195.
11. O'Brien P, Roos D, Pratt G, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000; 18:519-526.
12. Raizer JJ, DeAngelis LM, Zclenetz AD, et al. Activity of rituximab in primary central nervous system lymphoma. Proc Am Soc Clin Oncol 2000; 19:166a (Abstract #642).
13. Pels H, Schulz H, Schlegel U, et al. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003; 26:351-354.
14. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000; 46:51-60.
15. Guha-Thakurta N, Damek D, Pollack C, et al. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999; 43:259-268.
16. Holland BA. Diseases of white matter. In: Brant-Zawadzki M, Norman D, eds. Magnetic Resonance of the Central Nervous System. New York, NY: Raven 1987; 162:509-511.
17. Constine LS, Konski A, Ekholm S, et al. Adverse effects of brain irradiation correlated with MR and CT imaging. Int J Radiat Oncol Biol Phy 1988; 15:319-330.
18. Curran WJ, Hecht-Leavitt C, Schur L, et al. Magnetic resonance imaging of cranial radiation lesions. Int J Radiat Oncol Biol Phy 1987; 13:1093-1098.
19. Caveness WF, Carsten AL. Late effects of whole brain irradiation within the therapeutic range. In: Late Biological Effects of Ionizing Radiation, vol. 2. Vienna: International Atomic Energy Agency; 1978:221-239.
20. Bleyer WA, Griffin TW. White matter necrosis, mineralizing microangiopathy, and intellectual abilities in survivors of childhood leukemia. In: Gilbert HA, Kagan AR, eds. Radiation Damage to the Nervous System: A Delayed Therapeutic Hazard. New York, NY. Raven; 1980:155-174.